Korean Sunscreen vs American Sunscreen: Why Indie Brands Can't Just Import (2026)

By the ALTA MEET editorial team | K-beauty ODM consulting | NYC × Seoul

Reviewed for accuracy by ALTA MEET's formulation consulting team

Most indie founders walk into their first Korean ODM call assuming a sunscreen is a sunscreen. They have a Pinterest board of glassy Korean SPF textures. They have a Shopify mockup. They have a price target somewhere around eighteen dollars. Then the conversation hits a wall that nobody warned them about. The lab will be happy to formulate a beautiful Korean sunscreen at SPF 50+ PA++++. They simply cannot ship it into the United States the way the founder imagined.

This is the gap nobody explains until you are already deep into a brief. American sunscreens and Korean sunscreens are not two flavors of the same product. They are two regulatory categories built on two different lists of approved ingredients, two different test methods, and two different definitions of what a sunscreen even is. For an indie brand trying to launch in the US market, that gap turns into either a six-month reformulation project or an entire pivot away from sunscreen.

This guide is what we wish every founder read before the first ODM call. It is structured as a side-by-side comparison and ends with a decision framework so you can pick the path that fits your launch budget.

The Headline Difference at a Glance

The fastest way to see the gap is in a single table. Read it slowly, because every row is a contract clause waiting to happen.

DimensionSouth KoreaUnited StatesRegulatory classFunctional cosmetic (KFDA category)Over-the-counter (OTC) drugGoverning ruleKFDA Cosmetic Act / Functional Cosmetic Notification21 CFR Part 352 (sunscreen monograph, stayed indefinitely since 1999)Approved UV filters~30 organic filters plus inorganic ZnO and TiO216 listed; only 8 routinely used; only ZnO and TiO2 are formally GRASENewer-generation filters allowed (Tinosorb S, Tinosorb M, Uvinul A Plus, Uvinul T 150, Mexoryl SX/XL, DHHB)YesNo (one historical Mexoryl SX exception via La Roche-Posay 2006)SPF test methodISO 24444:2019 in vivo (and ISO 23698 in vitro)FDA Final Rule 1999 / OTC monograph test methodUVA markerPA system (PA+ to PA++++)"Broad Spectrum" pass/fail at critical wavelength 370 nmMoCRA applies?N/A (Korean rule)Sunscreens are OTC drugs, NOT cosmetics, so MoCRA scope is limited to non-active claimsManufacturing facilityKGMP (ISO 22716 compatible)Drug cGMP (21 CFR Part 211)Typical indie MOQ at ODM3,000 to 10,000 units5,000 to 50,000+ units at a US OTC contract manufacturerTypical landed cost per unit (50 ml SPF 50+)USD 3.50 to 6.50 finishedUSD 6 to 14 finished

The two columns are not slight variants. They are different worlds with different supply chains, different chemists, and different cost structures. The rest of the guide walks through each row so you know which trade-off you are signing for.

The UV Filter Approval Gap: The Single Most Important Difference

If you remember nothing else, remember this. The FDA has not approved a new sunscreen active ingredient in roughly 25 years. The last truly new filter to enter the US monograph was avobenzone, finalized in 1999. The Sunscreen Innovation Act of 2014 was supposed to clear the backlog. As of early 2026, the backlog is still mostly intact. In December 2025 the FDA finally proposed adding bemotrizinol, also known as Tinosorb S or BEMT, through the new OTC Tier 1 Monograph Order Request (OMOR) process sponsored by DSM-Firmenich. The expected GRASE determination is around March 2026, with consumer-available products possibly arriving in late 2026.

That is one filter, after eleven years.

Meanwhile the Korean and European regulators have been clearing newer filters on a regular cadence. Korean sunscreen formulators today routinely use Tinosorb S (bemotrizinol), Tinosorb M (bisoctrizole), Uvinul A Plus (diethylamino hydroxybenzoyl hexyl benzoate, DHHB), Uvinul T 150 (ethylhexyl triazone), and Mexoryl SX/XL (ecamsule and drometrizole trisiloxane). Each of these gives broader UVA coverage, better photostability, and lighter texture than the old US filter set built on oxybenzone, avobenzone, octinoxate, octisalate, homosalate, and octocrylene.

This is why Korean sunscreens feel cosmetically different. The chemistry is different. A Korean SPF 50+ PA++++ at 18% total active load can be water-light and fragrance-light. The US equivalent built on avobenzone plus octocrylene plus a homosalate booster typically needs a higher total active load, often 25 to 35%, which is why so many US-compliant sunscreens still feel heavy or smell strongly of solubilizers.

For an indie brand the implication is structural. You cannot import a Korean sunscreen with Tinosorb in it and sell it on Amazon US. The filter is not on the FDA monograph, the product is therefore an unapproved new drug, and Amazon, Shopify Markets, and US customs have all become measurably stricter on this in the last 24 months. Even Korean brands with US warehouses have started removing newer-generation filters from their US-facing SKUs.

SPF Testing and PA Ratings: Two Methodologies, Two Numbers

The SPF on the front of the bottle looks like a universal number. It is not.

Korean sunscreens are tested under ISO 24444:2019 (in vivo SPF determination) with the PA grading derived from the persistent pigment darkening (PPD) method that originated in Japan and was formalized through the Japan Cosmetic Industry Association in 1996. The PA score, from PA+ to PA++++, corresponds to bands of PPD value. ISO 24443 and the newer in vitro ISO 23698 (published December 2024) are both gaining adoption for UVA characterization.

US-bound sunscreens are tested under the FDA's own protocol from the 1999 Final Rule. The Minimal Erythemal Dose ratio principle is similar, but the panel selection, dose per unit area, time intervals, and statistical handling are different enough that an SPF number tested under ISO 24444 cannot be transferred onto a US label as-is. The FDA requires the test data on file with the OTC submission to come from a US-recognized lab using the FDA method.

For UVA the US uses a binary "Broad Spectrum" claim based on a critical-wavelength test at 370 nm. There is no PA equivalent on a US label. You can have a Korean PA++++ sunscreen that meets US Broad Spectrum, but the PA claim itself cannot appear on the US package.

For an indie founder this means the same physical product, even when the formula is reformulated to use only FDA-approved filters, still needs a separate test campaign for the US market. Budget USD 8,000 to 18,000 for a US in vivo SPF and Broad Spectrum testing package at a recognized clinical lab. ISO testing run in Korea does not substitute.

Regulatory Classification: OTC Drug vs Functional Cosmetic

This is the row most founders skim past and then deeply regret six months later.

In Korea, sunscreen sits inside the "functional cosmetic" notification framework under the KFDA Cosmetic Act. It is the same regulatory tier as whitening and anti-aging claims. The brand files a functional cosmetic notification with KFDA, supports it with the lab's efficacy data, and the product can ship. The factory operates under KGMP (Korean GMP), which is broadly compatible with ISO 22716 cosmetic GMP and aligns with how the rest of the Korean cosmetic stack is built.

In the US, sunscreen is an over-the-counter drug. The relevant rule is 21 CFR Part 352, which has technically been stayed indefinitely since 1999 while the FDA works through proposed orders, but in practice the 1999 monograph framework still governs the market. That means three concrete things for an indie brand. First, the active ingredient must be on the OTC monograph list (ZnO, TiO2, and the avobenzone family of organics). Second, the finished product must be manufactured in a facility registered under drug cGMP (21 CFR Part 211), not just cosmetic GMP. Third, the label must follow the OTC Drug Facts panel format, including "Active ingredient", "Purpose", "Uses", "Warnings", "Directions", "Inactive ingredients", and "Other information".

A common founder mistake is assuming MoCRA covers sunscreen because sunscreen sits in the beauty aisle. It does not. MoCRA (the Modernization of Cosmetics Regulation Act of 2022) covers cosmetics. Sunscreens with cosmetic claims that go beyond UV protection (for example, a tinted SPF marketed primarily as a foundation) live in a hybrid zone, but the SPF claim itself pulls the product into OTC drug rules regardless of how the front-of-pack reads. The MoCRA facility registration and product listing your contract manufacturer files for your moisturizer does not cover your sunscreen. Sunscreen needs its own FDA drug listing under the OTC framework.

The small business exemption inside MoCRA also does not help. MoCRA exempts businesses with under USD 1 million in average annual cosmetics sales over the prior three years from certain MoCRA requirements. That exemption applies to MoCRA's cosmetic rules, not to OTC drug rules. The OTC drug requirements apply at scale one.

If you want to read a deeper walk-through of how MoCRA and FDA OTC sit next to each other, the FDA Korean skincare import guide on our blog covers the parallel paperwork in detail, and the MoCRA compliance checklist for US brands manufacturing in Korea walks through the registration sequence step by step.

I'm Liz, I run altameet from Manhattan, NYC. Sunscreen is the single product category where I see indie founders lose three to six months of runway because nobody flagged the OTC drug rule before they signed an ODM PO. If you want a quick gut-check on whether to launch with sunscreen at all, or to start with a non-OTC SKU and add SPF in year two, I will give you fifteen minutes free. Book your free 15 min →.

Three Paths for an Indie Brand: Decision Framework

When a founder hits this fork, there are really only three honest paths. The fourth path, "ignore the rule and ship it anyway", is the path that ends with an Amazon ASIN takedown and a held shipment at the Port of Long Beach. We are not including it.

Path 1: Reformulate the Korean Product with US-Approved Filters

This is the most common path for founders who want the cosmetic feel of a Korean sunscreen but the regulatory cover of a US-eligible product.

The Korean ODM rebuilds the formula using only the FDA-approved actives. In practice that usually means a hybrid system of zinc oxide (for broad UV plus formal GRASE status) and avobenzone (for UVA depth), often with octocrylene as a photostabilizer for avobenzone and homosalate or octisalate as solubilizers. The final cosmetic texture is harder to keep weightless because the total active load is higher, but a skilled Korean lab can get within 80% of the original feel.

Timeline reality. A normal Korean ODM serum or moisturizer reformulation cycle is roughly eight to twelve weeks from brief to bulk-approved sample. A sunscreen reformulation is typically twelve to twenty-four weeks because you are revalidating SPF and UVA performance after every formulation iteration, and in vivo SPF testing alone takes four to six weeks per round. Budget six months from the brief if you want US-eligible final product.

Cost reality. Expect USD 3.50 to 7.00 finished cost per unit at 3,000 to 10,000 unit runs. Add USD 8,000 to 18,000 for the US SPF/UVA test package, USD 2,000 to 5,000 for stability and microbiology to drug cGMP standard, and USD 4,000 to 9,000 for OTC drug listing, label compliance review, and Responsible Person registration in the US. Year one regulatory burden lands around USD 18,000 to 35,000 on top of finished goods.

Path 2: Source from a US OTC Sunscreen Contract Manufacturer

This is the cleaner regulatory path. You skip the Korean ODM for sunscreen entirely and contract with a US OTC drug-registered facility, typically in New Jersey, Pennsylvania, or California.

Timeline reality. Faster on the regulatory side because the facility is already drug cGMP registered. Slower on the cosmetic feel side because most US OTC manufacturers are not built around Korean-style sensorial texture work. You will get a competent product, often built on the same avobenzone-octocrylene-ZnO stack.

Cost reality. US OTC contract manufacturer MOQs typically start at 5,000 to 10,000 units for an existing stock formula, climbing to 20,000 to 50,000 units for a custom formula. Finished cost usually lands USD 6 to 14 per unit before margin. The trade-off you are making is regulatory speed and predictability versus cosmetic differentiation.

Path 3: Skip Sunscreen in Year One, Build the Brand on Non-OTC SKUs First

This is the path we suggest most often to first-time founders with under USD 150,000 in launch capital. Sunscreen is a wonderful category for repeat purchase and basket-builder economics, but it is a punishing category to launch as your first SKU. Every non-OTC SKU you build (serums, essences, moisturizers, masks) ships under MoCRA cosmetic rules, which are dramatically simpler than OTC drug rules.

Build the brand on three non-OTC SKUs in year one. Develop the sunscreen reformulation in parallel with year-two budget. Ship the sunscreen in month thirteen or fourteen as a brand extension once your distribution channels are already moving units.

The opportunity cost of this path is that you start year one without the highest-frequency repurchase category. The savings is approximately USD 18,000 to 35,000 in year-one regulatory and testing burden that you redirect into product photography, retainer, and paid acquisition instead.

For a deeper look at how non-OTC Korean ODM cost structures work compared to sunscreen, our breakdown of Korean skincare manufacturing cost shows where the line items move when you remove the OTC layer.

Five Mistakes Indie Brands Make in This Category

After three years of watching founders work through this exact decision, the same five mistakes show up in the same order.

The first mistake is treating Korean sunscreen and US sunscreen as the same product with different labels. They are different chemistries built around different filter lists. Anything you import as a finished good with newer-generation filters is an unapproved new drug under FDA rules, and the customs and marketplace enforcement has tightened sharply in 2024 and 2025.

The second mistake is assuming MoCRA covers sunscreen. MoCRA covers cosmetics. Sunscreen is an OTC drug. Your MoCRA facility registration for a moisturizer does not extend to your SPF SKU. A sunscreen needs its own FDA drug establishment registration and product listing under the OTC framework.

The third mistake is budgeting only for the finished cost and not for the regulatory burden. The USD 18,000 to 35,000 testing and registration cost in year one frequently catches founders who built their financial model around a USD 5.00 cost-of-goods assumption. The OTC overhead is real, recurring (some elements annually), and not negotiable.

The fourth mistake is testing only under ISO 24444 in Korea and assuming the SPF claim transfers. It does not. The FDA accepts data only from its own protocol, run at a US-recognized facility. Plan and budget for the US SPF/UVA test campaign as a separate line item, with its own timeline.

The fifth mistake is choosing the most ambitious launch SKU first. Sunscreen is the highest-difficulty category in indie K-beauty. We suggest most first-time founders launch with a serum or moisturizer in year one (non-OTC, faster, cheaper, simpler) and add sunscreen as a year-two brand extension once they have working distribution and operating cash flow.

Key Takeaways

The single highest-impact realization is that Korean sunscreen and American sunscreen are different regulatory products. The Korean version is a functional cosmetic. The American version is an OTC drug. That single classification difference cascades into different filter lists, different test methods, different manufacturing standards, different labeling, and different registrations.

The second highest-impact realization is that you almost certainly need to reformulate, not import. The shortlist of newer-generation filters that make Korean sunscreens feel so wearable (Tinosorb S, Tinosorb M, Uvinul A Plus, Uvinul T 150, Mexoryl SX/XL) are not on the FDA's approved list. One of them, bemotrizinol (Tinosorb S), is under active review as of 2026 with a possible GRASE determination in March 2026, but the rest are still years away.

The third realization is that the cleanest path for most first-time indie founders is to delay sunscreen to year two. The category is high-trust, high-repeat, and high-margin, but the year-one regulatory burden of USD 18,000 to 35,000 on top of finished goods is hard to absorb at a sub-USD-150,000 launch budget. Building the brand on non-OTC SKUs first and adding sunscreen as a year-two extension is the path we suggest most often.

If you do want to launch with sunscreen in year one, build the reformulation on a Korean ODM that has a track record of US-compliant filter systems, plan twelve to twenty-four weeks for reformulation including SPF revalidation, and budget the US SPF/UVA test campaign and OTC drug listing into your pre-launch financial model from week one.

FAQ

Can I sell a Korean sunscreen with Tinosorb on Shopify in the US if I market it as "for personal use" or "skincare-only"?

No. The SPF claim plus a UV-protection claim brings the product into the FDA's OTC drug definition regardless of marketing language. "Skincare-only" framing does not change the regulatory classification of the product. Marketplace enforcement (Amazon, Shopify Markets, Sephora) has tightened on this in the last two years, and customs holds are increasingly common at high-volume ports.

Is the FDA going to approve Tinosorb S in 2026?

A GRASE determination is expected around March 2026 through the OTC Tier 1 Monograph Order Request (OMOR) process sponsored by DSM-Firmenich. If it clears, formulators expect consumer products containing bemotrizinol to appear in late 2026 in the US. Tinosorb M, Uvinul A Plus, Uvinul T 150, and the Mexoryl family are not in that same active-review pathway and remain unapproved for the US market in 2026.

Can I use my Korean ODM's KGMP facility for a US OTC sunscreen?

Only if that facility is also registered under US drug cGMP (21 CFR Part 211) and listed with the FDA as a drug establishment. Most Korean cosmetic ODMs are not. A growing minority of Korean ODMs have built drug cGMP-registered lines specifically to serve US-bound sunscreens. Ask your ODM for their FDA establishment registration number before assuming they can ship US-eligible SPF.

How much testing do I actually need for a US sunscreen launch?

At minimum: US in vivo SPF testing per the FDA monograph, Broad Spectrum critical wavelength test, water resistance (40 or 80 minute claim, if used) testing, finished product stability under ICH Q1A(R2)-style protocols, microbiological testing under ISO 17516:2014 limits (1,000 CFU/g leave-on, 100 CFU/g eye/pediatric/mucosal), and active ingredient assay. Budget USD 18,000 to 35,000 for the full first-year test campaign including label compliance review.

Why is the Korean SPF texture so different even at the same SPF rating?

The cosmetic feel comes from the filter chemistry. Newer-generation filters like Tinosorb S and Uvinul A Plus give broad UVA coverage at lower total active load, which means more room in the formula for water phase, lighter emollients, and Korean-style sensory boosters (squalane, snail mucin, fermented actives). US-eligible filter sets built on avobenzone plus octocrylene plus a homosalate or octisalate booster usually need 25 to 35% total active load, which forces a heavier base.

Is mineral-only (ZnO + TiO2) a path to a one-formula Korean and US launch?

It is the closest thing to a universal formula, but it is not a true single-SKU solution. Korean consumers expect a higher PA score and a lighter texture than a typical mineral-only formula can deliver at SPF 50+. The Korean version will likely add a UVA-extending organic filter that you cannot include in the US version. Even with mineral-only, you still need separate US SPF and UVA testing data because the FDA does not accept ISO 24444 data on the label.

Should I expect MOQ flexibility from a Korean ODM on sunscreen?

Less than for non-OTC SKUs. The minimum efficient batch size for a stable sunscreen emulsion is meaningfully higher than for a serum or a toner. Most Korean ODMs we work with set sunscreen MOQ at 3,000 units minimum, with cost breaks at 5,000 and 10,000 units. Some specialty labs will run 1,000 to 2,000 units at a per-unit cost premium of roughly 30 to 50%. For a deeper look at the brief template that gets indie founders to the best MOQ posture, see our step-by-step Korean ODM brief guide.

If you are in the middle of a sunscreen decision and want a fifteen-minute gut-check on which of the three paths fits your launch, book your free 15 min →. We do not pitch on these calls. We work through the regulatory math with you and tell you what we would do in your seat.

Reviewed for accuracy by ALTA MEET's formulation consulting team. Last updated 2026-05-21. Regulatory facts cross-checked against 21 CFR Part 352 (US OTC sunscreen monograph), KFDA Functional Cosmetic Notification framework, ISO 24444:2019 and ISO 23698 (sun protection test methods), MoCRA 2022, and the FDA's December 2025 OMOR Tier 1 proposal on bemotrizinol.